Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anticoagulant therapy in acute lung injury.
Laterre PF, Wittebole X, Dhainaut JF. Laterre PF, et al. Among authors: dhainaut jf. Crit Care Med. 2003 Apr;31(4 Suppl):S329-36. doi: 10.1097/01.CCM.0000057912.71499.A5. Crit Care Med. 2003. PMID: 12682461 Review.
Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.
Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S; CAPTIVATE Trial Group. Wunderink RG, et al. Among authors: dhainaut jf. Am J Respir Crit Care Med. 2011 Jun 1;183(11):1561-8. doi: 10.1164/rccm.201007-1167OC. Epub 2011 Feb 4. Am J Respir Crit Care Med. 2011. PMID: 21297074 Clinical Trial.
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Dhainaut JF, et al. Intensive Care Med. 2003 Jun;29(6):894-903. doi: 10.1007/s00134-003-1731-1. Epub 2003 Apr 24. Intensive Care Med. 2003. PMID: 12712239 Clinical Trial.
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.
Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, Sollet JP, Bates BM, Utterback BG, Maki D. Dhainaut JF, et al. Crit Care Med. 2003 Sep;31(9):2291-301. doi: 10.1097/01.CCM.0000085089.88077.AF. Crit Care Med. 2003. PMID: 14501959 Clinical Trial.
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J; Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators. Opal S, et al. Among authors: dhainaut jf. Crit Care Med. 2004 Feb;32(2):332-41. doi: 10.1097/01.CCM.0000108867.87890.6D. Crit Care Med. 2004. PMID: 14758145 Clinical Trial.
212 results